ReviewNature medicine2013
Regulation of hepatic innate immunity by hepatitis C virus.
Review in Nature medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 1 synthesis or guideline pooled it, 273 citations in OpenAlex.
- The m6A epitranscriptome opens a new charter in immune system logic.Epigenetics · 2021Pooled it
- PCBP2 inhibits antiviral innate immune responses via the MAVS-mediated signaling pathway in severe fever with thrombocytopenia syndrome.Virus research · 2026Article
- T cell dysfunction and metabolic disruption in chronic hepatitis C virus infection.Frontiers in immunology · 2026Review
- Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells.Cellular & molecular immunology · 2025Review
- Viral Hepatitis: Host Immune Interaction, Pathogenesis and New Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2024Review
- Biomarkers in Detection of Hepatitis C Virus Infection.Pathogens (Basel, Switzerland) · 2024Review
- Subversion of selective autophagy for the biogenesis of tombusvirus replication organelles inhibits autophagy.PLoS pathogens · 2024Article
- Immortalized hepatocyte-like cells: A competent hepatocyte model for studying clinical HCV isolate infection.PloS one · 2024Article
- Antiviral PROTACs: Opportunity borne with challenge.Cell insight · 2023Review
- Plerixafor and resatorvid inhibit hepatitis B virusFrontiers in cellular and infection microbiology · 2023Article
- Chronic HCV infection promotes cytotoxicity in antigen-specific CD8Frontiers in virology (Lausanne, Switzerland) · 2023Article
- Stochastic dynamics of Type-I interferon responses.PLoS computational biology · 2022Article
- A Human and Rhesus Macaque Interferon-Stimulated Gene Screen Shows That Over-Expression ofViruses · 2022Article
- Hepatitis C Virus Infection and Intrinsic Disorder in the Signaling Pathways Induced by Toll-Like Receptors.Biology · 2022Review
- Toll-like Receptor Response to Hepatitis C Virus Infection: A Recent Overview.International journal of molecular sciences · 2022Review
- Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes.PLoS pathogens · 2021Article
- Mitochondrial Modulations, Autophagy Pathways Shifts in Viral Infections: Consequences of COVID-19.International journal of molecular sciences · 2021Review
- 2-O-Methylhonokiol Suppresses HCV Replication via TRAF6-Mediated NF-kB Activation.International journal of molecular sciences · 2021Article
- Functional genetic variants of the IFN-λ3 (IL28B) gene and transcription factor interactions on its promoter.Cytokine · 2021Article
- Initial HCV infection of adult hepatocytes triggers a temporally structured transcriptional program containing diverse pro- and anti-viral elements.Journal of virology · 2021Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hepatitis C virus (HCV) is a global public health problem involving chronic infection of the liver, which can cause liver disease and is linked with liver cancer. Viral innate immune evasion strategies and human genetic determinants underlie the transition of acute HCV infection to viral persistence and the support of chronic infection. Host genetic factors, such as sequence polymorphisms in IFNL3, a gene in the host interferon system, can influence both the outcome of the infection and the response to antiviral therapy. Recent insights into how HCV regulates innate immune signaling within the liver reveal a complex interaction of patient genetic background with viral and host factors of innate immune triggering and control that imparts the outcome of HCV infection and immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.